In Clinical

Follow this topic

Bookmark

Record learning outcomes

Entresto (sacubitril plus valsartan) is now available for adults with symptomatic chronic heart failure with reduced ejection fraction. Novartis says that sacubitril plus valsartan reduces the risk of cardiovascular death and first hospitalisation for heart failure by 20 per cent when compared to enalapril, equivalent to an absolute risk reduction of 4.7 per cent.